Cardiac safety in the European Stroke Prevention Study 2 (ESPS2)
Related Experiment Video
Updated: Oct 7, 2026
Real-Time Electrocardiogram Monitoring During Treadmill Training in Mice
Published on: May 5, 2022
H C Diener1, H Darius, J M Bertrand-Hardy
1Dept of Neurology, University of Essen, Hufelandstrasse 55, 45122 Essen, Germany.
Abstract:
The second European Stroke Prevention Study investigated the prevention of stroke and/or death in 6602 patients with transient ischaemic attack or stroke with aspirin (25 mg b.d.), dipyridamole (400 mg b.d.), the combination of aspirin and dipyridamole or placebo. This post hoc analysis investigated cardiac events in patients with coronary heart disease or myocardial infarction (MI) at entry. Dipyridamole did not result in a higher number of cardiac events, e.g. angina pectoris, MI, or death from all causes. The combination of aspirin plus dipyridamole was superior to either drug alone in the prevention of stroke.
Related Concept Videos
01:21Cardiac Catheterization II: Right Heart Catheterization
01:30Cardiac Action Potential
The cardiac action potential process involves a series of phases characterized by the movement of ions across the cardiac cell membranes, leading to the depolarization and repolarization of the cardiac myocytes.
Ionic Basis of Cardiac Action Potentials